Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.
Ishido S, Tamaki N, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Izumi N. Ishido S, et al. Among authors: itakura j. JGH Open. 2023 Jul 21;7(8):567-571. doi: 10.1002/jgh3.12950. eCollection 2023 Aug. JGH Open. 2023. PMID: 37649865 Free PMC article.
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Kaneko S, et al. Among authors: itakura j. J Gastroenterol Hepatol. 2019 Nov;34(11):2004-2010. doi: 10.1111/jgh.14686. Epub 2019 May 21. J Gastroenterol Hepatol. 2019. PMID: 31017689
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Kirino S, et al. Among authors: itakura j. J Gastroenterol Hepatol. 2020 Sep;35(9):1595-1601. doi: 10.1111/jgh.14990. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31975419
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Takahashi Y, Izumi N. Tamaki N, et al. Among authors: itakura j. J Med Virol. 2020 Aug;92(8):1355-1358. doi: 10.1002/jmv.25692. Epub 2020 Feb 7. J Med Virol. 2020. PMID: 31994737
Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir.
Tamaki N, Kurosaki M, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: itakura j. JGH Open. 2019 Oct 24;4(3):429-432. doi: 10.1002/jgh3.12273. eCollection 2020 Jun. JGH Open. 2019. PMID: 32514449 Free PMC article.
Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib.
Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Kurosaki M, Izumi N. Kaneko S, et al. Among authors: itakura j. JGH Open. 2020 Oct 16;4(6):1183-1190. doi: 10.1002/jgh3.12420. eCollection 2020 Dec. JGH Open. 2020. PMID: 33319054 Free PMC article.
Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Kaneko S, et al. Among authors: itakura j. J Gastroenterol Hepatol. 2021 Oct;36(10):2943-2951. doi: 10.1111/jgh.15563. Epub 2021 Jun 16. J Gastroenterol Hepatol. 2021. PMID: 34057248
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis.
Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Inada K, et al. Among authors: itakura j. JGH Open. 2021 Aug 19;5(9):1085-1091. doi: 10.1002/jgh3.12636. eCollection 2021 Sep. JGH Open. 2021. PMID: 34584979 Free PMC article.
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Miyake S, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: itakura j. J Hepatol. 2008 May;48(5):736-42. doi: 10.1016/j.jhep.2007.12.025. Epub 2008 Feb 26. J Hepatol. 2008. PMID: 18329125
175 results